<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322957</url>
  </required_header>
  <id_info>
    <org_study_id>CTRV-FV-1-008</org_study_id>
    <nct_id>NCT02322957</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ContraVir Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ContraVir</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the potential for a PK drug-drug interaction between&#xD;
      FV-100 and ritonavir. The study is a single-center, open-label, randomized, 2-way crossover&#xD;
      design in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of safety of a single oral dose of FV-100 alone and when combined with a single oral dose of ritonavir</measure>
    <time_frame>Two weeks</time_frame>
    <description>Measuring the Cmax, Tmax and AUC for FV-100 pk profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The evaluation of the pharmacokinetics of FV-100 and CF-1743 following a single oral dose of FV-100 administered alone and with a single oral dose of ritonavir</measure>
    <time_frame>Two weeks</time_frame>
    <description>Measuring the Cmax, Tmax and AUC for FV-100 pk profile when dosed with ritonavir</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Treatment Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FV-100 400mg OD as a single dose fasted (&gt;/= 8 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FV-100 400 mg OD as a single dose with ritonavir 200mg OD as a single fasted dose (&gt;/= 8 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FV-100</intervention_name>
    <description>Subjects will be randomized to one of two treatment sequences: AB or BA.</description>
    <arm_group_label>Treatment Regimen A</arm_group_label>
    <arm_group_label>Treatment Regimen B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of giving written informed consent&#xD;
&#xD;
          -  Non-tobacco user for at least 3 months prior to selection&#xD;
&#xD;
          -  Healthy on the basis of physical examination, medical history, ECG and clinical&#xD;
             laboratory testing at screening&#xD;
&#xD;
        Exclusion Criteria:(must NOT meet the following)&#xD;
&#xD;
          -  Infected with Hepatitis A, B, C, or HIV&#xD;
&#xD;
          -  History of or any current medical condition which could impact safety of the&#xD;
             participant&#xD;
&#xD;
          -  A positive urine drug test&#xD;
&#xD;
          -  Consumption of more than 2 units of alcoholic beverages per day or more than 14 per&#xD;
             week&#xD;
&#xD;
          -  Received an investigational drug or vaccine or used an investigational medical device&#xD;
             within 3 months or 5 half-lives before the planned start of treatment or prior&#xD;
             treatment with FV-100&#xD;
&#xD;
          -  Subjects who have used any drugs or substances known to inhibit or induce&#xD;
             cytochrome(CYP) P450 enzymes and/or P-gp within 28 days prior to the first dose and&#xD;
             throughout study&#xD;
&#xD;
          -  Subjects who have, within 2 weeks prior to the first dose of study drug, ingested&#xD;
             grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard&#xD;
             green family or charbroiled meats&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>December 15, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

